Localized Drug Action for safe and effective kinase inhibitors

Amakem is a clinical stage ophthalmology company developing innovative new treatments for serious eye conditions. The Company’s lead program is based on AMA0076, a novel, locally-acting Rho kinase (ROCK) inhibitor, in clinical development for the treatment of glaucoma, a condition which damages the optic nerve resulting in vision loss and ultimately blindness.

Amakem's product pipeline is based on its unique 'Localized Drug Action' platform which generates kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.


Recent News
Mar 20, 2014 Amakem’s Localized Drug Action Platform and AMA0076 Pre-Clinical Data Highlighted in New Publications
Mar 4, 2014 Amakem Appoints Dr. James Tsai of the Yale School of Medicine to its Clinical Advisory Board